In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first
punch setting the stage and the second delivering the knock-out. This analogy can be …

The progressive growth and expansion of solid tumors beyond microscopic sizes of about 1-
2 mm in diameter requires the formation of new blood vessels-a process known as tumor …

Publisher Summary This chapter outlines studies that define HER-2/neu-specific immunity in
patients with cancer and overviews the current vaccine strategies for generating or …

Carcinoma of the stomach is one of the most prevalent cancer types in the world today. Two
major forms of gastric cancer are distinguished according to their morphological and …

The anti Her‐2/neu monoclonal antibody Trastuzumab has strong inhibiting effects on tumor
growth in vitro and in vivo and is therefore used for immunotherapy in breast cancer patients …

Abstract HER-2/neu (also known as HER2 or c-erb-B2) is a 185-kDa protein receptor with
tyrosine kinase activity and extensive homology to the epidermal growth factor (EGF) …

The tyrosine kinase inhibitors PD 69896, 153717, and 158780, which belong to the
chemical class 4-[ar (alk) ylamino] pyridopyrimidines, have been characterized with respect …

ErbB family members represent important biomarkers and drug targets for modern precision
therapy. They have gained considerable importance as paradigms for oncoprotein addiction …

The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of
cancers overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a …

The tumour antigen ErbB-2 belongs to the epidermal growth factor receptor family.
Numerous studies have shown that ErbB-2 is overexpressed in many cancers and it is …